TAC新辅助化疗方案治疗HER-2阳性乳腺癌的疗效  

The efficacy of TAC neoadjuvant chemotherapy regimen for HER-2 positive breast cancer

作　　者：麻丽珍[1] 潘静进 MA Li-zhen;PAN Jing-jin(Galactophore Department,Maternal and child health care hospital of Huadu District,Guangzhou City,Guangdong Province(Huzhong hospital),Guangzhou 510800,China)

机构地区：[1]广州市花都区妇幼保健院(胡忠医院)乳腺科,广东广州510800

出　　处：《吉林医学》2022年第10期2632-2634,共3页Jilin Medical Journal

摘　　要：目的:探讨多西他赛+吡柔比星+环磷酰胺(TAC)新辅助化疗方案治疗人类表皮生长因子受体2(HER-2)阳性乳腺癌的疗效。方法:选取HER-2阳性乳腺癌患者65例为研究对象,依据化疗方案分为TAC组(n=33)和TEC组(n=32),TAC组给予TAC新辅助化疗,TEC组给予TEC(多西他赛+表柔比星+环磷酰胺)新辅助化疗,比较两组细胞因子[HER-2、细胞核相关抗原Ki-67(Ki67)]、疗效、生存及不良反应情况。结果:TAC组和TEC组治疗后HER-2、Ki67低于治疗前,TAC组治疗后HER-2、Ki67低于TEC组(P<0.05);TAC组治疗有效率、中位生存时间高于TEC组(P<0.05);TAC组不良反应率低于TEC组(P<0.05)。结论:TAC新辅助化疗方案可降低HER-2阳性乳腺癌患者HER-2、Ki67,有利于提高疗效,且安全性好。Objective To discuss the efficacy of TAC neoadjuvant chemotherapy regimen for human epidermal growth factor receptor 2(HER-2) positive breast cancer. Method Sixty-five patients with positive HER-2 breast cancer were selected as research object, and they were divided into TAC group(n=33) and TEC group(n=32) according to chemotherapy regimen. TEC group was received TEC(docetaxel + epirubicin + cyclophosphamide) neoadjuvant chemotherapy, TAC group was received TAC(docetaxel + pirarubicin + cyclophosphamide) neoadjuvant chemotherapy, the cytokines [HER-2, nuclear associated antigen 67(Ki67)], efficacy, survival and adverse reactions were compared. Results The the HER-2 and Ki67 after treatment in TAC group and TEC group were lower than those in before treatment, the HER-2 and Ki67 after treatment in TAC group were lower than those in TEC group(P<0.05). The effective rate and median survival time in TAC group were higher than those in TEC group(P<0.05). The rate of adverse reactions in TAC group was lower than that in TEC group(P<0.05). Conclusion TAC neoadjuvant chemotherapy can reduce the HER-2 and Ki67 in patients with HER-2 positive breast cancer, which is helpful to improve the efficacy, it has good safety.

关 键 词：TAC新辅助化疗方案 人类表皮生长因子受体2 细胞核相关抗原67 乳腺癌 疗效 

分 类 号：R737.9[医药卫生—肿瘤]